Skip to content
Karyopharm to Participate in Upcoming Investor Conferences

NEWTON, Mass.May 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that the Company’s management team will participate in the following upcoming investor conferences: 

  • The Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019, and will present at 3:00 p.m. ET.
  • The JMP Securities 2019 Life Sciences Conference on Wednesday, June 19, 2019, and will present at 11:30 a.m. ET.

A live webcast of the presentations can be accessed on the "Events & Presentations" page in the Investors section of the Company's website,  A replay of each webcast will be archived on the Company's website for 90 days following the presentation.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has several investigational programs in clinical or preclinical development. For more information, please visit


Karyopharm Therapeutics Inc.
Ian Karp
Vice President, Investor and Public Relations
857-297-2241 |

Argot Partners
David Rosen
212-600-1902 |


Source: Karyopharm Therapeutics Inc.

I agree to the storing and processing of my personal data by Karyopharm as described in the Privacy Policy and to the Terms of Use . I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.